Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Tulane researchers race to develop rapid Ebola finger-prick test: http://www.nola.com/health/index.ssf/2014/10/tulane_researchers_race_to_dev.html
Generous gesture down CDC rathole: http://www.nydailynews.com/news/world/zuckerberg-wife-donate-25m-cdc-ebola-article-1.1973632 Would be better spent at university or private research facility.
Very interesting!
OK- "GO OXBT"!!!!. Rah rah rah, shish boom bah!!
Recognition of March as Brain Injury Awareness Month: http://www.prnewswire.com/news-releases/brain-injury-association-of-washington-provides-national-leadership-in-concussion-safety--awareness-85837267.html
Thanks,biloxikid!
Good find seeray! Here's the link: http://www.clinicaltrials.gov/ct2/show/NCT00908063?term=oxycyte&rank=1
We're on the NASDAQ tower. Check it out. Same link as webcast. http://tinyurl.com/95reb
OxyBioMed LINK - Reminder: Chris Stern rings the NASDAQ Opening Bell at 9:30 a.m. Will be webcast live at NASDAQ site. Link: http://tinyurl.com/95reb
Chris Stern Blog - http://eshareholderforum.com/oxbo/Chris_Stern/
Trading on the NASDAQ
January 13, 2010, 7:54 pm
The New Year is off to a great start for Oxygen Biotherapeutics, Inc. It began with the achievement of one of our major near-term goals – to get our stock listing off of the Bulletin Board and onto a major exchange. Our shares will be trading on the NASDAQ starting this Friday, January 15. I plan to be at the Exchange to ring the opening bell on Jan. 22. Watch for video of that on our website, or be at Times Square in New York City for viewing on the big screen.
Having our shares listed on the NASDAQ will give our company visibility to a broad range of potential investors who could not or would not have considered investing in our stock when it was on the Bulletin Board. Most of the big institutional investors (mutual funds, pension funds, etc.) will not buy penny stocks (which we were pre-split) nor buy shares that are not traded on a major exchange. Likewise, many retail brokerage firms cannot recommend such stocks to their clients. Being listed on the NASDAQ could lead to greater interest in our common stock by the broader financial community and the investing public. This re-listing is an important opportunity to position our company where we believe it belongs. It will give us the potential financial strength needed to become a company with multiple products in various development stages.
Speaking of multiple products, at today’s OneMedForum conference, I mentioned our plans for new product developments. I think some of those plans are pretty exciting.
First of all, we’re adding an additional pillar to our business strategy – veterinary products. Our research has come up with an animal wound-care product line for topical application. It takes the healing ability of Oxycyte™ in a gel form and makes it available to apply to pets, farm animals, etc. Because it is a topical product line for animals, we believe we can bring it to market very quickly. If you think about how much Americans spend on their pets, you can see that the potential could be very significant. Our goal is to have these products, which we have tentatively named OxyBioPet, on the market this year.
We plan to follow that with a second veterinary product line, which we are initially calling OxyBioVet. This would be an intravenous Oxycyte emulsion veterinarians could use to carry oxygen to an animal’s heart, brain or other organs. While I am not willing, right now, to predict the timing for a market launch, the requirements for animal products are far less restrictive than for humans.
At the same investor conference, I also briefly mentioned our plans to expand our cosmetic product line this year. We are targeting this spring to roll out our Dermacyte Eye Cream. It is formulated for those fine line wrinkles around the eyes. We will also launch another formulation as a face lotion, and a repackaged version of our cosmetic concentrate gel, which we recently tested in blister packs via on-line sales. As a fourth product, we’re considering the Dermacyte Oxygenating Solution (DOS). Think of it as a perfluorocarbon liquid in its basic, clear form – not a gel or a cream but the PFC liquid with its ability to capture oxygen from the air and carry it through the outer skin layer.
Meanwhile, our TBI clinical trials are under way. It’s not likely that we will be providing any additional information until some time after the first cohort has been treated and the results analyzed. While enrollment of the first patient was delayed for reasons previously explained, I’m confident that we’re on a time line to complete the trial in the targeted 12 to 18 months.
2010 began with a major milestone and I expect the whole year to bring others. Thank you for your support. Stay tuned; stay healthy, wealthy, and safe. God bless.
Dermacyte Upcoming products 2010 : New Dermacyte Oxygen Concentrate & Dermacyte Oxygen Eye Cream! http://bit.ly/8jXmld
24 minutes ago from Facebook
Oxygen (OTCBB: OXBT) did not reveal what its Nasdaq ticker would be. http://triangle.bizjournals.com/triangle/stories/2010/01/04/daily63.html
From Twitter: OxyBioMed Check out the new Oxycyte video on the company website at www.oxybiomed.com. Video link is on the front page. What do you think?
about 1 hour ago from web
Chris Stern statement re: shipment of Dermacyte from FaceBook and Twitter links:
http://www.oxybiomed.com/video/v_cstern_home.htm
Correction #3772 - Date at MarketWatch is Nov 6, 2009, 12:00 a.m.
MarketWatch has OXBT moving up, but no movement in my Scottrade streaming quotes. http://www.marketwatch.com/investing/stock/oxbt
CNNMoney is reporting: http://money.cnn.com/news/newsfeeds/articles/prnewswire/200911061605PR_NEWS_USPR_____LA06966.htm
I don't think I've seen them pick up a report on OXBO or SYBD before.
Thanks for your report, fineware!
Noting the presence of security is very interesting. Perhaps someone who attended the CA meeting last year can provide perspective.
It is. Thanks, wisardd1!
Re: #3531 - I thought it might bear watching. We might get a heads up on what OXBO is doing by keeping an eye on what they're doing.
For instance, bingster's find of the 10/19/09 store shelf availability date for Dermacyte on www.accentuatestaffing.com provided new information from an unlikely source.
Has this company been mentioned here?
http://www.theoxfordgroup.com/
Check out their biotech clients:
http://www.theoxfordgroup.com/c-biotechnology-clients.htm
I'm aware of the ramifications and agree with you on the dilution/AS issue.
At least the sixes are in groups of four instead of three. ;)
You sound like you're in much the same position as I. For 8-10 years I've picked up a few shares at a time. I would go literally years without even checking the price, so did miss opportunities to increase the few thousand shares I hold.
My stock purchases have been limited to a dollar amount I would be willing to kiss goodbye, although I do not want to plant my lips at the point of a gun with a R/S.
But for belief in the potential of the product(s) and my interest in TBI, SYBD/OXBO would have disappeared from my portfolio long ago.
My inclination regarding the vote is to follow a life-long rule: If in doubt . . . don't.
Email ProxyVote heads up. 9-19-09
xanadau, you are welcome. Sorry I couldn't be more helpful.
I recall the oops email event the same and the group emails being halted. The only difference is that my notes indicate an April date instead of March.
According to my notes, the accidental PR release dates were April 13/14, 2008. Are we talking about the same event?
Unfortunately, I did not copy my email to the computer I bought in May, so I do not have the group list.
The explanatory letter issued by Abe stated the following:
"About 500 people have signed up to receive SYBD news releases via email. They are sent in batches of 100."
I hope that's helpful in determining how many people would constitute as complete a list as possible.
Peripheral product website: http://www.buydermacyte.com/index.htm
09/08/09 Oxygen Biotherapeutics, Inc. Submits Milestone Achievement Notice to Vatea Fund
http://www.oxybiomed.com/investors.htm
DURHAM, N.C., Sept. 8 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) announced that it has formally notified Vatea Fund of the company's achievement of a milestone under the Securities Purchase Agreement dated June 8, 2009, as amended September 1, 2009. The milestone is a Clinical Trial for Oxycyte in Traumatic Brain Injury Approved by Swissmedic.
With the achievement of the milestone, the agreement calls for Vatea Fund to purchase 24 million shares of Oxygen Biotherapeutics stock from the company for $6 million with the transaction to close no later than December 10, 2009.
About Oxygen Biotherapeutics, Inc.
Oxygen Biotherapeutics is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and Defense Medicine(TM). The company has under development a perfluorocarbon (PFC) therapeutic oxygen carrier and liquid ventilation product (Oxycyte(R)) and has out-licensed an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs as well as medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including traumatic brain injury, sickle cell crisis, trauma, wound care, decompression sickness, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, diabetes wounds and ulcers, and cosmetic applications. More information is available at www.oxybiomed.com.
SOURCE Oxygen Biotherapeutics, Inc.
Abe Wischnia, Abe Wischnia & Associates, +1-619-795-2345
08/14/09 Oxygen Biotherapeutics, Inc. to Begin Oxycyte(R) Phase II Clinical Trials in Switzerland
DURHAM, N.C., Aug 14, 2009 /PRNewswire-FirstCall via COMTEX/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) today announced that the company has received approval to begin a Phase II, dose escalation, clinical trial in Switzerland for use of Oxycyte(R) in traumatic brain injury (TBI). Oxycyte is the Company's perfluorocarbon (PFC) therapeutic oxygen carrier.
"This approval from Swissmedic means that we can begin enrolling patients," said Chris Stern, company chairman and CEO. "Our people have worked very hard to achieve this major milestone for our company. This trial is of invaluable importance in improving the outcome of patients with severe TBI. We hope to finally prove that there is a safe and effective treatment for this devastating injury."
The company has named the 128 patient study "Safety and Tolerability of Oxycyte in Patients with Traumatic Brain Injury" or "STOP TBI". The first patient is expected to be enrolled in September. Since study participants will all be emergency cases, it is not possible to pinpoint a date for the actual first patient.
A contract research organization (CRO), PFC Pharma Focus AG, will supervise the study. The principal investigator is Dr. Michael Reinert of the Department of Neurosurgery at the University Hospital of Berne. The Insel Hospital in Berne will be the first of the planned seven trial centers in Switzerland and four in Israel to begin enrolling patients. The other trial centers planned for the Swiss study are in Zurich, Aarau, St. Gallen, Basel, Geneva and Lausanne.
"We have a premier CRO to manage the Swiss trials and what I consider to be some of the best neurosurgeons in Switzerland as clinical investigators along with leading Swiss hospitals as study sites," said Stern. "Because of the way we are structuring the trials and the quality of the Swiss medical community, we should have data compliant with the requirements of a multi-national study that can be submitted to the FDA as well as Swissmedic."
The dose escalation studies will focus on finding the lowest dose of Oxycyte that provides clinical benefit in traumatic brain injury while minimizing adverse effects. Dose levels of Oxycyte would start at 1.0 ml/kg body weight and escalate in steps to 2.0 ml/kg, and 3.0 ml/kg for subsequent patient cohorts. Escalation of dose will only occur after a favorable review of safety data by an independent Data Safety Monitoring Board.
About Oxygen Biotherapeutics, Inc.
Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and Defense Medicine(TM). The company has under development a perfluorocarbon (PFC) therapeutic oxygen carrier and liquid ventilation product (Oxycyte(R)) and has out-licensed an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs as well as medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including traumatic brain injury, sickle cell crisis, trauma, wound care, decompression sickness, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, diabetes wounds and ulcers and cosmetic applications. More information is available at www.oxybiomed.com.
Caution Regarding Forward-Looking Statements
This news release contains certain forward-looking statements by Oxygen Biotherapeutics, Inc. that involve risks and uncertainties and reflect the company's judgment as of the date of this release. These statements include those referring to the start of a Phase II clinical trial in Switzerland for Oxycyte in TBI and time frame estimate for enrolling patients. Actual events or results may differ from Oxygen Biotherapeutics, Inc.'s expectations. There can be no assurance that a sufficient number of patients will be enrolled in the trial nor any assurance of the outcomes. Additional information concerning these and other risk factors affecting Oxygen Biotherapeutics, Inc.'s business can be found in the company's public periodic filings with the Securities and Exchange Commission, which are available via www.oxybiomed.com. Oxygen Biotherapeutics, Inc. disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
SOURCE Oxygen Biotherapeutics, Inc.
http://www.oxybiomed.com
Wisardd1, thanks for the heads up. The episode is "Pay Up" and the blood line is delivered by Gary Sinise. He may have provided the influence to insert the "synthetic blood" information into the episode because he is a big military supporter, is involved in the USO and Operation Iraqi Children.
Link to watch is here: http://www.cbs.com/primetime/csi_ny/
NEWS - http://www.oxybiomed.com/pages/InvestorRelations.html
Oxygen Biotherapeutics, Inc. to Launch Product Line of Oxycyte(R) Gels for the Over-the-Counter Market
COSTA MESA, Calif.--(BUSINESS WIRE)--Mar. 17, 2009-- Oxygen Biotherapeutics, Inc. (OTCBB:OXBO) today announced that the company will move ahead with a line of gels based on Oxycyte®. The first and most basic gel based on Oxycyte will be formulated to enhance its topical cosmetic properties. Oxycyte is the company's perfluorocarbon (PFC) therapeutic oxygen carrier.
The company intends to market the first Oxycyte Gel as a cosmetic which provides a moist, oxygen-rich environment for the skin. No therapeutic claim for healing will be made for this baseline, cosmetically-formulated Oxycyte Gel.
“Our first product is now very close to market readiness,” said Chris J. Stern, company chairman and CEO. “The regulatory process for such products is uncomplicated and straightforward. Laboratory testing of the cosmetic formulation should be completed in the second quarter along with the packaging design. We are now ready to start the processes of identifying and signing license and distribution partners. The progress we’re making with the topical gel should give us good momentum to launch our more complex over-the-counter product initiatives.”
Simultaneously, the company is pushing development of the second OTC product, which will be designated as a topical, therapeutic, non-prescription drug intended to provide a moist, oxygen-rich environment to promote healing of minor skin wounds. While it will require safety and clinical testing, the pre-IND (Investigational New Drug) process has already been initiated, and a detailed critical path will be decided after the pre-IND exchange with the FDA. “We should have the best of both worlds, a fast-track marketable product and, in its footsteps, a highly effective wound treatment with superb potential,” Stern stated further. “We will be working towards exploring this further and, with a third product line, try to reach deep into the highly profitable surgical environment.”
IMO, Good! eom
The "stimulus" bill and our investment in R&D technologies. http://www.bloomberg.com/apps/news?pid=20601039&refer=columnist_mccaughey&sid=aLzfDxfbwhzs
Pertinent excerpt:
The stimulus bill does that, and calls it the Federal Coordinating Council for Comparative Effectiveness Research (190-192). The goal, Daschle’s book explained, is to slow the development and use of new medications and technologies because they are driving up costs. He praises Europeans for being more willing to accept “hopeless diagnoses” and “forgo experimental treatments,” and he chastises Americans for expecting too much from the health-care system.
Hope everyone here is under 40.
Steelers7, here is a link to Phase II results -
http://www.clinicaltrials.gov/ct2/show/NCT00174980?term=Oxycyte&rank=1
Golfnut, I'm staying in although today's activity and the belated email have put me into the P.O.'d camp.
OXBO isn't mentioned in the announcement, but there's an FDA blood products meeting on January 9, 2009:
Meeting of the Blood Products Advisory Committee
http://www.fda.gov/cber/advisory/bp/bp0109.htm
LegalView Reports of New Traumatic Brain Injury Treatment Study Publishing Positive Results for Brain-Injured Victims
http://www.prweb.com/releases/2008/11/prweb1638144.htm